Stay updated with breaking news from Director Eric Andersen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $12.55 and traded as high as $13.47. Merrimack Pharmaceuticals shares last traded at $13.44, with a volume of 29,917 shares traded. Analysts Set New Price Targets Separately, StockNews.com […]
StockNews.com lowered shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) from a hold rating to a sell rating in a report issued on Tuesday. Merrimack Pharmaceuticals Stock Down 0.4 % MACK stock opened at $13.25 on Tuesday. The business has a fifty day moving average of $13.10 and a two-hundred day moving average of $12.52. […]
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.40 and traded as high as $13.39. Merrimack Pharmaceuticals shares last traded at $13.32, with a volume of 36,749 shares. Analyst Ratings Changes Separately, StockNews.com upgraded shares […]
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) Director Eric Andersen bought 101,050 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was bought at an average cost of $12.85 per share, for a total transaction of $1,298,492.50. Following the completion of the transaction, the director now directly […]
StockNews.com began coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Merrimack Pharmaceuticals Trading Up 1.5 % NASDAQ MACK traded up $0.18 on Thursday, hitting $12.19. 26,084 shares of the company’s stock traded hands, […]